Christos Socrates Mantzoros is a Greek-born American internist-endocrinologist, teacher, and researcher. He is a professor of medicine at Harvard Medical School and an adjunct professor at Boston University School of Medicine. In the past, he has also served as a professor at the Harvard T.H. Chan School of Public Health.
He is certified in internal medicine, endocrinology, and metabolism in both Europe and the United States, and serves as the chief of endocrinology, diabetes, and metabolism at the VA Boston Healthcare System. Mantzoros is the founding Director of Human Nutrition at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, and Editor-in-Chief of the journal "".
Mantzoros served as a board member on the Hellenic College Holy Cross, as well as the ALBA Graduate Business School of the American College of Greece board of trustees.
Mantzoros' research is primarily focused on topics such as human physiology and molecular biology, observational epidemiology studies, and clinical trials treating obesity, diabetes, and other human metabolic diseases. Leptin has been approved by the United States Food and Drug Administration (FDA) for treating lipodystrophy and severe insulin resistance accompanied by hyperglycemia and hyperlipidemia.
His publications consist of two books, more than 1,100 scientific papers, and he has conducted over 135 clinical trials.
Mantzoros heads Mantzoros Consulting, LLC. In 2005, he co-founded Intekrin, Inc., which was later acquired by and merged with Coherus, Inc.
Mantzoros teaches at Harvard Medical School and Boston University School of Medicine.
He is on the ALBA Graduate Business School of the American College of Greece Board of Trustees.
Mantzoros is the recipient of the following awards:
Other (selected) awards include: